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COMPARISON OF DOSING PROFILES BETWEEN DULOXETINE AND 
PREGABALIN INITIATORS AMONG ELDERLY PATIENTS WITH 
FIBROMYALGIA
Sun P1, Peng X2, Wu A3, Zhao Y2
1Kailo Research Group, Indianapolis, IN, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 
3Kailo Research Group, Los Angeles, CA, USA
OBJECTIVES: To assess dosing differences between duloxetine and pregabalin initia-
tors among elderly patients with ﬁbromyalgia. METHODS: Using a large US admin-
istrative claims database, we examined ﬁbromyalgia patients aged 65 and above with 
Medicare supplemental insurance who initiated duloxetine or pregabalin in 2006. 
Initiation was deﬁned as no duloxetine or pregablin pill coverage in the previous 90 
days, with the index date deﬁned as the ﬁrst initiation date. The duloxetine or prega-
balin cohorts were constructed based on the index agent. All individuals selected had 
continuous enrollment in the 12 months pre- and post-index periods and at least 31 
duloxetine or pregabalin supply days in the 12 months post-index period. Duloxetine 
initiators with diabetic peripheral neuropathic pain (DPNP) or depression, and pre-
gabalin initiators with DPNP, post-herpetic neuralgia or epilepsy diagnosis in the 
12-month pre-index period were excluded. Average initial daily dose, annual average 
daily dose, average daily dose of the ﬁrst 12 prescriptions of duloxetine or pregabalin, 
and percent of daily dose change from previous prescription were compared between 
cohorts. RESULTS: Patients in the duloxetine (n = 624) or pregabalin (n = 1,199) 
cohorts had a mean age of 74 years. The average initial daily dose was 51.34 mg for 
duloxetine and 145.71 mg for pregabalin, respectively. Duloxetine patients had an 
annual average daily dose of 50.81 mg, while 162.82 mg for pregabalin patients. The 
average daily dose for the ﬁrst through twelfth duloxetine prescriptions ranged 49.49–
53.96 mg, while the range for pregabalin was between 145.71 mg and 216.96 mg. 
The percentages of changes in daily dose from previous prescriptions were −4.5–2.8% 
for duloxetine and 0.6–12.4% for pregabalin, respectively. CONCLUSIONS: Dulox-
etine and pregabalin had very different dosing proﬁles among elderly patients with 
ﬁbromyalgia. Speciﬁcally, duloxetine initiators had relatively stable average daily dose 
over time, while pregabalin initiators had clear dose escalation over the 12-month 
follow-up period.
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OBJECTIVES: Obesity (deﬁned as body mass index (BMI) > 30) is a major contributor 
to increased morbidity, mortality, and health care expenditures. We used data from 
the Medical Expenditure Panel Survey (MEPS) to construct a lifetime cost and out-
comes model explicitly accounting for morbid obesity. Then, we estimated the poten-
tial economic value of weight reduction in terms of cost savings plus the value of 
improvements in life expectancy and quality of life. METHODS: We constructed a 
Markov model with a lifetime horizon using death and BMI health states: 18.5–24.9, 
25–29.9, 30–34.9, 35–35.9, 40–44.9, 45–49.9, 50 < . MEPS Panels 6–10 (2001–2006) 
provide 91,000 observations to estimate transition probabilities. We estimated dis-
counted (3% per annum) lifetime costs and quality-adjusted life years (QALYs) using 
regressions with gender, age, and BMI as predictors. Utilities were mapped from SF-12 
to EQ-5D. RESULTS: In the base case, for a 45 year-old female with BMI 45–49.9, 
a 10%, 20%, and 30% BMI reduction is associated with discounted lifetime economic 
value gain of $20,000, $35,000, and $51,000, respectively. Transition probability 
estimates show that patients tend to stay in the same BMI category from year to year. 
Average annual cost increases signiﬁcantly (p < 0.01) with BMI (+$362 per 5 BMI 
unit increase), age (+$118 for each year of age) and gender (+$547 for females). For 
utility levels, BMI (−0.0246 per 5 BMI unit increase), age (−0.0036 for each year of 
age), and gender (−0.0355 for females) were all signiﬁcant (p < 0.01). CONCLU-
SIONS: MEPS panels provide repeated measures of BMI allowing a projection of the 
natural history of obesity from a single data source. Obesity is a signiﬁcant driver of 
costs and QALYs: we show that a reduction in BMI of obese patients could be associ-
ated with lower costs and better quality-adjusted life expectancy. MEPS provides only 
self-reported BMI data, and this potential bias deserves further exploration.
PSY22
COST-EFFECTIVENESS OF STRATEGIES FOR DIAGNOSING HEPARIN-
INDUCED THROMBOCYTOPENIA
Patel V, Touchette D, Yang Y, Nutescu E, Kim KS, Vidanovic V, Galanter W
The University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: Heparin-induced thrombocytopenia (HIT) is an immune-mediated 
complication of heparin therapy. Accurate diagnosis reduces the need for unnecessary 
treatment, which can result in bleeding complications. The objective of this study was 
to identify the most cost-effective strategy (Enzyme-linked immunosorbent assay 
(ELISA) vs. ELISA/Serotonin Release Assay (SRA)) for diagnosing HIT from the health 
system perspective. METHODS: Multiple decision-analysis models were constructed 
using TreeAge Pro software following the ISPOR task force guidelines for modeling. 
The 2008 American College of Chest Physician’s Guidelines were used to inform HIT 
treatment approaches. A systematic literature search was used to identify all model 
inputs such as the effectiveness of argatroban, heparin, and warfarin; weighted costs 
and disutilities for overall thrombosis and bleeding complications; and costs of acute 
events and long-term complications. Mean age-adjusted quality of life of a healthy 
patient was estimated using life tables. Costs and quality-adjusted life years (QALYs) 
were discounted at 5%. Base-case values were determined using Monte Carlo simula-
tion and sensitivity analyses were conducted. Net beneﬁt of each strategy was analyzed 
at different willingness-to-pay (WTP) thresholds ($0 to $150,000) to determine the 
most cost-effective strategy. RESULTS: In the base-case, ELISA resulted in lifetime 
costs and utilities of $9028 and 10.5413 QALYs compared with $8849 and 10.5428 
QALYs for ELISA/SRA. ELISA was dominated by ELISA/SRA. ELISA/SRA was the 
most cost-effective strategy for WTP thresholds between $25,000 and $150,000; 
ELISA was optimal for WTP thresholds under $25,000. ELISA/SRA remained cost-
effective when thrombosis and bleeding complication costs and probabilities were 
varied. ELISA was the most cost-effective strategy when speciﬁcity was greater than 
92.7%. The results were consistent for both prophylactic and treatment doses of 
unfractionated heparin. CONCLUSIONS: For the base-case scenario, ELISA/SRA is 
the optimal testing strategy. Health care providers need to take into account the 
turnaround time for ELISA and SRA results for generalizing the study ﬁndings.
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A COST-EFFECTIVENESS ANALYSIS OF CONVENTIONAL TREATMENT 
VERSUS BARIATRIC SURGERY FOR OBESE PATIENTS WITH TYPE-2 
DIABETES AND HYPERTENSION AS COMORBIDITIES. PRELIMINARY 
RESULTS UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
Nasciben V, Saggia MG
Johnson & Johnson, Sao Paulo-SP, Brazil
OBJECTIVES: To assess the cost-effectiveness of the open (OPBARS) and the lapa-
roscopic surgery Roux-en-Y gastric bypass (LAPBARS) versus the conventional non-
surgical treatment (CONVT) for obese patients, in 5 years of follow up, under the 
Brazilian private payer perspective. METHODS: An analytic decision-tree model was 
built to estimate costs and outcomes among OPBARS and LAPBARS versus CONVT, 
measuring weight loss, co morbidities resolution (T-2 diabetes and hypertension; 
Buchwald 2009) and the impact of that on QALYs for obese patients with BMI > 35. 
In order to evaluate the differences of surgery against CONV treatment we assumed 
the same efﬁcacy for OPBARS and LAPBARS. The Brazilian guideline for Health 
Technology Assessment (Vianna, 2007) was the driver for the study development. A 
panel of specialists was conducted to obtain local practice from pre-operatory evalu-
ation to the last medical visit 5 years after the procedure. A micro costing technique 
based on public price lists (SIMPRO 2009, CBHPM 5o Ed) was applied to value the 
resources usage. Only direct medical costs were considered. A discount rate of 5% 
was assumed for costs and outcomes. One-way sensitivity analysis was performed to 
check the robustness of the results. RESULTS: The more sustainable resolution of the 
co morbidities for OPBARS and LAPBARS resulted in an increase of 1.34 QALYs in 
5 years versus CONVT (3.26 QALYs vs. 1.92 QALYs). The total costs for the 5 years 
were R$ 26, 456 for OPBARS, R$ 32,515 for LAPBARS and R$ 19,217 for CONVT. 
So, the incremental cost-effectiveness ratio was R$ 7,449 per QALY for OPBARS 
and R$ 10,395 per QALY for LAPBARS when compared with CONVT. 
CONCLUSIONS: Findings suggest OPBARS and LAPBARS as safer and cost-effective 
choices for obesity treatment and co morbidity resolution, under the Brazilian private 
health care system.
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COST-EFFECTIVENESS OF HAEMATE P® PROPHYLACTIC TREATMENT 
FOR BLEEDING EPISODES IN PATIENTS WITH SEVERE VON 
WILLEBRAND DISEASE
Gonzalez-Diaz BE1, Contreras I2, Martinez-Murillo C1, Alvarez J3, Fuentes-Mendez F3
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OBJECTIVES: Patients with sever von Willebrand disease (VWD) are deﬁcient in von 
Willebrand factor (VWF). These deﬁciencies can result in painful and sometimes fatal 
bleeding. The purpose of this study is to develop an economic model for the evaluation 
of cost-effectiveness ratios between Haemate P® and other plasma-derived FVIII/VWF 
concentrates treatment in the control or prophylaxis of urgent bleeding of patients 
with von Willebrand Disease at the Mexican Institute of Social Security (IMSS). 
METHODS: A cost-effectiveness analysis was developed using a Bayesian decision-
tree model. The model simulates costs and effectiveness outcomes in a period of 2O 
days. The comparators were Haemate P® (loading dose 40–60 kg-1 and maintenance 
dose 20–40 U kg-1 every 8–24 h) and plasma-derived FVIII/VWF (dose 20 −50 U 
Kg-1 every 8–24 h). Use of resources and cost data were obtained from expert con-
sensus with hematologist of IMSS. Effectiveness measures were the percentage of 
avoided bleeding. Effectiveness data and transition probabilities were taken from 
international published literature. The model was calibrated according to international 
pharmacoeconomic guidelines. One-way and probabilistic sensitivity analyses were 
performed using second-order Monte Carlo Simulation approach. RESULTS: The 
estimates show that patients who receive Haemate P® prevents might bleeding events 
in 97% while those treated with plasma-derived FVIII/VWF only in the 82%. Mean 
cost per patient treated with Haemate P® (US$4932) was lower than with plasma-
derived FVIII/VWF (US$5,010). Based on ICER’s Haemate P® resulted as the domi-
nant therapy. Acceptability curves showed Haemate P® most cost-effective therapy in 
a range of 80%–90% independently of IMSS willingness to pay. CONCLUSIONS: 
The results show that in México, Haemate P® is the most cost-effective in the pro-
phylaxis of bleeding in patients with VWD at IMSS. These results should be taken 
into account by Mexican decision makers for the management of this disease.
